Your browser doesn't support javascript.
loading
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase.
Xie, Stanley C; Wang, Yinuo; Morton, Craig J; Metcalfe, Riley D; Dogovski, Con; Pasaje, Charisse Flerida A; Dunn, Elyse; Luth, Madeline R; Kumpornsin, Krittikorn; Istvan, Eva S; Park, Joon Sung; Fairhurst, Kate J; Ketprasit, Nutpakal; Yeo, Tomas; Yildirim, Okan; Bhebhe, Mathamsanqa N; Klug, Dana M; Rutledge, Peter J; Godoy, Luiz C; Dey, Sumanta; De Souza, Mariana Laureano; Siqueira-Neto, Jair L; Du, Yawei; Puhalovich, Tanya; Amini, Mona; Shami, Gerry; Loesbanluechai, Duangkamon; Nie, Shuai; Williamson, Nicholas; Jana, Gouranga P; Maity, Bikash C; Thomson, Patrick; Foley, Thomas; Tan, Derek S; Niles, Jacquin C; Han, Byung Woo; Goldberg, Daniel E; Burrows, Jeremy; Fidock, David A; Lee, Marcus C S; Winzeler, Elizabeth A; Griffin, Michael D W; Todd, Matthew H; Tilley, Leann.
Afiliação
  • Xie SC; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Wang Y; School of Pharmacy, University College London, London, WC1N 1AX, UK.
  • Morton CJ; Biomedical Manufacturing Program, CSIRO, Clayton South, VIC, Australia.
  • Metcalfe RD; Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
  • Dogovski C; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Pasaje CFA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Dunn E; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Luth MR; Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
  • Kumpornsin K; Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK.
  • Istvan ES; Calibr, Division of the Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Park JS; Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
  • Fairhurst KJ; Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
  • Ketprasit N; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY, 10032, USA.
  • Yeo T; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA.
  • Yildirim O; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Bhebhe MN; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY, 10032, USA.
  • Klug DM; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA.
  • Rutledge PJ; Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Godoy LC; School of Chemistry, University of Sydney, Camperdown, NSW, 2006, Australia.
  • Dey S; School of Pharmacy, University College London, London, WC1N 1AX, UK.
  • De Souza ML; School of Chemistry, University of Sydney, Camperdown, NSW, 2006, Australia.
  • Siqueira-Neto JL; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Du Y; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Puhalovich T; Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
  • Amini M; Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
  • Shami G; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Loesbanluechai D; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Nie S; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Williamson N; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Jana GP; Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK.
  • Maity BC; Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Thomson P; Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia.
  • Foley T; TCG Lifesciences Private Limited, Salt-Lake Electronics Complex, Kolkata, India.
  • Tan DS; TCG Lifesciences Private Limited, Salt-Lake Electronics Complex, Kolkata, India.
  • Niles JC; School of Chemistry, The University of Edinburgh, Edinburgh, EH9 3JJ, UK.
  • Han BW; School of Chemistry, The University of Edinburgh, Edinburgh, EH9 3JJ, UK.
  • Goldberg DE; Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Burrows J; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Fidock DA; Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
  • Lee MCS; Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
  • Winzeler EA; Medicines for Malaria Venture, 20, Route de Pré-Bois, 1215, Geneva 15, Switzerland.
  • Griffin MDW; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY, 10032, USA.
  • Todd MH; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA.
  • Tilley L; Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA.
Nat Commun ; 15(1): 937, 2024 Jan 31.
Article em En | MEDLINE | ID: mdl-38297033
ABSTRACT
Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development. In vitro evolution of resistance using a slow ramp-up approach pointed to the Plasmodium falciparum cytoplasmic asparaginyl-tRNA synthetase (PfAsnRS) as the target, consistent with our finding that OSM-S-106 inhibits protein translation and activates the amino acid starvation response. Targeted mass spectrometry confirms that OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. Human AsnRS is much less susceptible to this reaction hijacking mechanism. X-ray crystallographic studies of human AsnRS in complex with inhibitor adducts and docking of pro-inhibitors into a model of Asn-tRNA-bound PfAsnRS provide insights into the structure-activity relationship and the selectivity mechanism.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspartato-tRNA Ligase / Antimaláricos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspartato-tRNA Ligase / Antimaláricos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article